Diabetic Ketoacidosis Market to Grow with a CAGR of 5.35% through 2028
Raising awareness about Diabetic Ketoacidosis and its
management are expected to drive the Global Diabetic Ketoacidosis Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Diabetic
Ketoacidosis Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Diabetic Ketoacidosis Market
stood at USD 3.24 billion in 2022 and is anticipated to grow with a CAGR of 5.35% in the forecast period, 2024-2028.
The Global Diabetic Ketoacidosis (DKA) Market is
experiencing substantial growth, driven by a combination of factors that are
reshaping the landscape of diabetes management and treatment. DKA is a
life-threatening complication of diabetes, characterized by hyperglycemia and
the presence of ketones in the blood. In recent years, the market for DKA
management has witnessed a surge in demand, and several key drivers are
propelling its growth and innovation. One of the primary drivers behind the
growth of the Global DKA Market is the escalating prevalence of diabetes. Among
these individuals, those with Type 1 diabetes are particularly vulnerable to
DKA. As the diabetic population continues to expand worldwide due to lifestyle
changes, obesity, and genetics, the incidence of DKA cases is also on the rise,
fueling the demand for DKA management solutions.
Heightened awareness about diabetes and its
complications, including DKA, has played a crucial role in driving market
growth. Public health campaigns, patient education initiatives, and advocacy
groups have been instrumental in promoting early diagnosis and management of
diabetes and DKA. People are now more informed about the risk factors,
symptoms, and importance of regular glucose monitoring, which has led to
earlier intervention and improved outcomes. This increased awareness has
spurred greater demand for DKA-related products and services. The advancement
of technology in glucose monitoring has revolutionized diabetes management and
has a significant impact on the DKA market. Continuous glucose monitoring (CGM)
systems, for example, provide real-time data on glucose levels, helping
individuals make informed decisions about insulin dosing and carbohydrate
intake. CGM technology has not only improved the quality of life for people
with diabetes but also reduced the risk of DKA episodes by enabling better
glycemic control.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Diabetic
Ketoacidosis Market.”
The development of innovative insulin delivery systems
has been a key driver in the DKA market. Traditional insulin injections have
given way to insulin pumps and smart pens, which offer more precise and
convenient ways of administering insulin. These devices have the potential to
reduce the risk of insulin underdosing or overdosing, which are common triggers
for DKA. Moreover, some insulin pumps are equipped with predictive algorithms
that can help users proactively prevent hypoglycemia and hyperglycemia, further
mitigating the risk of DKA.
The Global Diabetic Ketoacidosis Market is segmented
into Treatment, End User,Regional Distribution, And Company.
Based on the Treatment, Insulin therapy emerged as the
dominant segment in the global market for Global Diabetic Ketoacidosis Market
in 2022. The primary reason for this is that insulin is the cornerstone of DKA
management. DKA is characterized by elevated blood sugar levels and the presence
of ketones in the blood, and insulin is the only treatment that directly
addresses these underlying issues.
Insulin
therapy effectively reduces blood glucose levels by facilitating the uptake of
glucose into cells and inhibiting the production of ketones. It helps correct
the metabolic abnormalities associated with DKA, ultimately resolving the
condition and preventing its life-threatening complications.
However, without insulin therapy to address the root
cause of DKA, these supportive measures alone cannot effectively manage the
condition. Therefore, insulin therapy remains the primary and most crucial
treatment modality in the DKA market, driving its demand and importance in DKA
management.
Based on the End User, the Hospitals and Clinics
segment emerged as the dominant player in the global market for Global Diabetic
Ketoacidosis Market in 2022. The primary reason for this preference is rooted
in the severity of DKA episodes and the need for immediate and comprehensive
medical care. DKA is a
life-threatening medical emergency that requires prompt intervention and close
monitoring. Hospitals and clinics are equipped with the necessary medical
infrastructure, including intensive care units, emergency departments, and
specialized healthcare professionals who are experienced in managing critical
cases like DKA. This acute care setting ensures that patients receive immediate
attention and appropriate treatment.
Hospitals and clinics have access to advanced
diagnostic and laboratory facilities, which are essential for confirming the
diagnosis of DKA, assessing electrolyte imbalances, and monitoring blood
glucose levels. Accurate and timely diagnostic capabilities are crucial in
tailoring the treatment to each patient's specific needs.
North America emerged as the dominant player in the
global Diabetic Ketoacidosis Market in
2022, holding the largest market share.
North America, particularly the United States and Canada, has one of the
highest prevalence rates of diabetes in the world. The increasing incidence of
diabetes, including both Type 1 and Type 2 diabetes, directly contributes to a
larger population at risk of DKA. This high prevalence drives the demand for
DKA-related products and services. High levels of patient awareness and
education about diabetes and its complications, including DKA, are prevalent in
North America. Healthcare organizations, advocacy groups, and educational
institutions actively promote diabetes awareness and provide resources to
empower patients to manage their condition effectively.
North America is a hub for clinical research and
trials in the field of diabetes. The region's participation in cutting-edge
research and clinical studies fosters innovation and drives the development of
new DKA management strategies and therapies.
Major companies operating in Global Diabetic
Ketoacidosis Market are:
- Novo Nordisk AS
- Baxter Healthcare Corporation
- B. Braun Medical Inc.
- ICU Medical, Inc.
- Pfizer Inc.
- Merit Pharmaceutical
- SteriCare Solutions
- Soxa Formulations & Research (Pvt.) Ltd
- BD company
- Fresenius Kabi USA
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Diabetic Ketoacidosis (DKA) Market is poised for substantial growth in the coming
years. Several key factors are driving this anticipated expansion. Firstly, the
rising global prevalence of diabetes, fueled by factors like sedentary
lifestyles and poor dietary habits, is leading to a larger population at risk
of DKA. Secondly, technological advancements in glucose monitoring, insulin
delivery systems, and pharmaceuticals are enhancing diabetes management and,
consequently, reducing the incidence of DKA. Thirdly, heightened awareness and
education about diabetes and its complications are leading to earlier diagnosis
and more proactive prevention efforts. Additionally, favorable healthcare
policies and reimbursement mechanisms are improving access to essential
DKA-related treatments and devices. Lastly, ongoing research and development
efforts are likely to yield innovative solutions for DKA management” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Diabetic Ketoacidosis Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement), By End
User (Hospitals & Clinics, Ambulatory Care Centres, Others) By Region and
Competition”, has evaluated the future growth potential of Global Diabetic
Ketoacidosis Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Diabetic
Ketoacidosis Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com